歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01672 歌礼制药-B

交易中 11-06 14:15:45

4.580

-0.315

-6.44%

最高4.755	最低4.545	成交量149.90万
今开4.710	昨收4.895	日振幅4.29%
总市值48.18亿	流通市值48.18亿	总股本10.52亿
成交额693.78万	换手率0.14%	流通股本10.52亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01672","market":"HK","secType":"STK","nameCN":"歌礼制药-B","latestPrice":4.58,"timestamp":1793945741955,"preClose":4.895,"halted":0,"volume":1499000,"delay":0,"changeRate":-0.06435137895812043,"floatShares":1052000000,"shares":1052000000,"eps":-0.3701,"marketStatus":"交易中","change":-0.315,"latestTime":"11-06 14:15:45","open":4.71,"high":4.755,"low":4.545,"amount":6937786,"amplitude":0.042901,"askPrice":4.58,"askSize":4000,"bidPrice":4.565,"bidSize":5000,"shortable":3,"etf":0,"ttmEps":-0.675455,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1793952600000},"marketStatusCode":2,"adr":0,"listingDate":1533052800000,"exchange":"SEHK","adjPreClose":4.895,"openAndCloseTimeList":[[1793928600000,1793937600000],[1793941200000,1793952000000]],"volumeRatio":0.580739,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01672","defaultTab":"news","newsList":[{"id":"1101374116","title":"歌礼制药-B：11月5日回购20万股股份，总额约96.06万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1101374116","media":"公告速递","labels":["shareholding","SGX"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101374116?lang=zh_cn&edition=full","pubTime":"2026-11-05 18:16","pubTimestamp":1793873788,"startTime":"0","endTime":"0","summary":"歌礼制药-B于2026年11月5日公告，再次在香港联交所场内回购股份。本次回购数量为20万股，占公司已发行股份约0.019%。回购价格最高每股4.925港元、最低4.66港元，合计支付约96.06万港元。经此次回购后，公司已发行股份数仍为1,052,202,859股，库藏股数量5,784,210股，总股本合计1,057,987,069股。根据公司于2026年6月29日通过的购回授权，公司可回购的股份总数为106,137,084股，截至目前累计已回购5,695,000股，占授权时公司已发行股份总数约0.5366%。上述公告由公司秘书钟明辉签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"歌礼制药-B：11月5日回购20万股股份，总额约96.06万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681402830","title":"歌礼制药-B(01672)11月5日斥资96.06万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2681402830","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681402830?lang=zh_cn&edition=full","pubTime":"2026-11-05 18:11","pubTimestamp":1793873491,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，于2026年11月5日，该公司斥资96.06万港元回购20万股股份，每股回购价4.66-4.925港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1519135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01477","BK1161","BK1515","01672","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170069944","title":"歌礼制药-B（01672.HK）向42名员工授出180万份购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1170069944","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170069944?lang=zh_cn&edition=full","pubTime":"2026-11-04 22:05","pubTimestamp":1793801126,"startTime":"0","endTime":"0","summary":"歌礼制药-B11月4日晚间公告称，公司已根据2025年2月3日采纳的购股权计划，于2026年11月4日向42名员工参与者授出共计1,800,000份购股权，涉及同等数量的新普通股，每股面值0.0001美元。公告称，除董事会另行决定并在授出要约中指明外，上述购股权在行使或归属前一般无须达到任何业绩目标；所有购股权均受购股权计划所载回拨机制约束。在本次授出后，2025年购股权计划项下可供未来授出的股份上限为31,291,225股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680057816","title":"歌礼制药-B(01672)授出180万份购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2680057816","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680057816?lang=zh_cn&edition=full","pubTime":"2026-11-04 22:04","pubTimestamp":1793801051,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)公布，公司于2026年11月4日向42名参与者授出购股权以认购合共180万股公司每股面值0.0001美元的普通股，所授出购股权的行使价为每股股份4.923港元，有效期10年。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1574","BK1191","01672","01477","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192587757","title":"歌礼制药-B更新10月股份变动月报，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1192587757","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192587757?lang=zh_cn&edition=full","pubTime":"2026-11-04 16:56","pubTimestamp":1793782612,"startTime":"0","endTime":"0","summary":"2026年11月4日，歌礼制药有限公司披露截至2026年10月31日止的证券变动月报。报告显示，公司本月未发生新增发行或库存股变动，整体股本结构保持稳定。根据公告，截至本月底，公司法定股本规模维持7,000,000,000股，面值每股0.0001美元，法定股本总额约70万美元。公司确认符合香港联交所对上市公司所要求的公众持股量规定。公告最后由公司秘书钟明辉签署。公司声明将继续遵守香港联交所《上市规则》及相关法律法规，并保持正常的信息披露。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680124377","title":"港股异动 | 创新药概念股延续跌势 金斯瑞生物科技(01548)跌超15% 康诺亚-B(02162)跌近5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680124377","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680124377?lang=zh_cn&edition=full","pubTime":"2026-11-03 14:45","pubTimestamp":1793688352,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，创新药概念股延续跌势，截至发稿，金斯瑞生物科技跌15.66%，报30.16港元；歌礼制药-B跌7.68%，报4.39港元；荣昌生物跌5.46%，报62.3港元；康诺亚-B跌4.88%，报63.3港元。消息面上，在此次ESMO大会上，有部分药物数据不及预期。另有一款HER2 ADC全球III期达到主要终点PFS，但潜在获益有限。市场人士表示，不可忽视创新药研发风险。政策实质是收紧股权类合作，而非阻断产品出海。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517676.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01548","159992","KCAI","BK4588","06978","BK1161","BK1576","VXUS","HK0000320264.USD","BK1583","09995","IBBQ","MEDX","LU2328871848.SGD","LNGR","HK0000306685.HKD","BK1574","02162","BK4585","BK1141","BK1515","HK0000320223.HKD","HK0000306701.USD","LU1969619763.USD","01672","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144936727","title":"歌礼制药-B（01672）将携两款减肥新药临床前成果亮相2026年ObesityWeek®","url":"https://stock-news.laohu8.com/highlight/detail?id=1144936727","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144936727?lang=zh_cn&edition=full","pubTime":"2026-11-02 16:46","pubTimestamp":1793609196,"startTime":"0","endTime":"0","summary":"2026年11月2日，歌礼制药-B发布自愿性公告称，公司旗下两款用于肥胖症治疗的候选药物——口服小分子GIPR激动剂ASC48及GLP-1R/GIPR/GCGR三靶点激动剂多肽ASC37——的最新临床前研究成果将以壁报形式在2026年ObesityWeek大会上展示。该会议将于2026年11月14日至17日在美国华盛顿特区举行。公司董事会主席兼首席执行官吴劲梓博士表示，将利用ObesityWeek的平台展示“高度差异化”的肥胖症管线最新进展。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680734792","title":"歌礼制药-B(01672.HK)：歌礼将携口服小分子GIPR激动剂ASC48和GLP-1R/GIPR/GCGR三靶点激动剂多肽ASC37的研究结果亮相2026年肥胖周(ObesityWeek®)","url":"https://stock-news.laohu8.com/highlight/detail?id=2680734792","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680734792?lang=zh_cn&edition=full","pubTime":"2026-11-02 16:42","pubTimestamp":1793608974,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1574","BK1191","01477","BK1515","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162644338","title":"歌礼制药-B回购30万股股份，耗资约150.02万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1162644338","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162644338?lang=zh_cn&edition=full","pubTime":"2026-10-30 17:56","pubTimestamp":1793354184,"startTime":"0","endTime":"0","summary":"2026年10月30日，歌礼制药有限公司在香港联交所发布翌日披露报表，披露已于当日于联交所场内回购30万股普通股，占公司已发行股本约0.0285%。本次回购每股价格在4.85港元至5.25港元之间，合计动用资金1,500,185港元。上述回购股份尚未注销，后续将按相关程序进行注销。公告显示，公司已于2026年6月29日通过股份回购授权，授权总量为106,137,084股。公司确认，此次回购符合香港联合交易所有限公司证券上市规则及相关法律的规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"歌礼制药-B回购30万股股份，耗资约150.02万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679291138","title":"歌礼制药-B(01672.HK)10月30日耗资约150.02万港元回购30万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2679291138","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679291138?lang=zh_cn&edition=full","pubTime":"2026-10-30 17:54","pubTimestamp":1793354064,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1515","BK1574","01477","BK1161","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140490256","title":"歌礼制药-B：10月29日回购10万股，耗资约52.54万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1140490256","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140490256?lang=zh_cn&edition=full","pubTime":"2026-10-29 17:36","pubTimestamp":1793266577,"startTime":"0","endTime":"0","summary":"歌礼制药有限公司于2026年10月29日发布翌日披露报表，公告显示，公司在香港联交所场内回购普通股10万股，约占当日已发行股本0.0095%。回购价格区间介乎每股5.185港元至5.305港元，总耗资约52.54万港元。公告称，回购完成后，公司已发行股本维持在1,052,202,859股，库藏股数量则保持5,784,210股。同时，歌礼制药-B已于2026年6月29日通过回购授权，授权总数为106,137,084股。截至目前，公司在香港联交所或其他证券交易所合计回购股份5,195,000股，占回购授权时已发行股本的约0.4895%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"歌礼制药-B：10月29日回购10万股，耗资约52.54万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679799514","title":"歌礼制药-B(01672)10月29日耗资约52.54万港元回购10万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2679799514","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679799514?lang=zh_cn&edition=full","pubTime":"2026-10-29 17:35","pubTimestamp":1793266559,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)公布，2026年10月29日耗资约52.54万港元回购10万股股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1515194.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01672","01477","BK1191","BK1161","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679479959","title":"歌礼制药-B(01672.HK)10月29日耗资约52.54万港元回购10万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2679479959","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679479959?lang=zh_cn&edition=full","pubTime":"2026-10-29 17:35","pubTimestamp":1793266559,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01477","01672","BK1515","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679544598","title":"歌礼制药：ASC30治疗2型糖尿病的美国II期研究取得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2679544598","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679544598?lang=zh_cn&edition=full","pubTime":"2026-10-29 08:04","pubTimestamp":1793232290,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1161","01477","BK1515","BK1574","01672","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679443709","title":"歌礼制药-B(01672)：GLP-1口服小分子ASC30在糖尿病受试者中进行的美国II期研究第12周时实现经安慰剂校正后的糖化血红蛋白(HbA1c)下降达1.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679443709","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679443709?lang=zh_cn&edition=full","pubTime":"2026-10-29 07:42","pubTimestamp":1793230934,"startTime":"0","endTime":"0","summary":"主要终点是第12周时糖化血红蛋白相较基线的下降;次要终点之一是第13周时体重相较基线的下降。主要终点方面，与安慰剂相比，ASC30在糖尿病受试者中实现了具有统计学显著性和临床意义的糖化血红蛋白下降。受试者基线平均糖化血红蛋白为8.3%。糖尿病受试者中观察到的良好胃肠道耐受性与在肥胖或超重受试者中进行的研究中的发现一致。就所有其他安全性信号而言，ASC30在糖尿病受试者中展现出良好的安全性特征。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1514778.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01672","BK1574","JDOC","BK1191","BK1515","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159834570","title":"歌礼制药-B（01672）公布ASC30美国II期糖尿病研究积极顶线数据：12周HbA1c最高降1.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1159834570","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159834570?lang=zh_cn&edition=full","pubTime":"2026-10-29 07:36","pubTimestamp":1793230570,"startTime":"0","endTime":"0","summary":"2026年10月29日，歌礼制药-B发布自愿性公告称，其自主研发的口服小分子GLP-1受体激动剂ASC30在美国开展的Ⅱ期2型糖尿病临床研究取得积极顶线结果。受试者基线平均HbA1c为8.3%。歌礼制药在公告中提醒，依据香港联交所证券上市规则第18A.05条，公司无法保证最终能成功实现ASC30的商业化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180582150","title":"歌礼制药-B：10月27日回购10万股，耗资约54.06万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1180582150","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180582150?lang=zh_cn&edition=full","pubTime":"2026-10-27 17:43","pubTimestamp":1793094202,"startTime":"0","endTime":"0","summary":"歌礼制药有限公司于2026年10月27日发布翌日披露报表，公告当日回购普通股股份100,000股。该回购数量约占公司已发行股本的0.0095%。本次回购每股价格最高为5.445港元、最低为5.355港元，合计支出540,570港元。本次回购后，公司已发行股本维持在1,052,202,859股，库藏股数为5,784,210股，总股本为1,057,987,069股。公司声明已遵守相关上市规则及当地适用法律法规，公告由公司秘书钟明辉签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"歌礼制药-B：10月27日回购10万股，耗资约54.06万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129549584","title":"歌礼制药-B10月26日回购10.00万股，耗资约55.88万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1129549584","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129549584?lang=zh_cn&edition=full","pubTime":"2026-10-26 18:21","pubTimestamp":1793010087,"startTime":"0","endTime":"0","summary":"歌礼制药有限公司于2026年10月26日发布翌日披露报表，披露当日股份回购相关事项。\\n\\n公司当日通过香港联交所场内交易方式回购普通股合计10.00万股，占已发行股本约0.0095%。回购价格介乎每股5.47港元至5.84港元，合计支付约55.88万港元。公司于2026年6月29日获批准购回不超过106,137,084股股份，截至公告日，已累计回购股份总数为4,995,000股。公司确认，本次回购行为已遵守香港联合交易所有限公司证券上市规则及相关法规的规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"歌礼制药-B10月26日回购10.00万股，耗资约55.88万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678164815","title":"歌礼制药-B(01672)10月26日斥资约55.88万港元回购10万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2678164815","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678164815?lang=zh_cn&edition=full","pubTime":"2026-10-26 18:21","pubTimestamp":1793010066,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，于2026年10月26日该公司斥资约55.88万港元回购10万股，回购价格为每股5.47至5.84港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1512544.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1161","BK1191","BK1574","BK1515","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678132140","title":"歌礼制药-B(01672)：口服小分子选择性胰淀素受体激动剂ASC39治疗肥胖症的新药临床试验申请已递交美国FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2678132140","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678132140?lang=zh_cn&edition=full","pubTime":"2026-10-26 08:23","pubTimestamp":1792974236,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，已向美国食品药品监督管理局递交ASC39口服片的新药临床试验申请。ASC39口服片是一款口服小分子选择性胰淀素受体激动剂，用于治疗肥胖症。ASC39是一种对胰淀素具有选择性的强效口服小分子胰淀素受体激动剂，正在既作为单药开发，也作为与ASC30联用开发，以治疗包括肥胖症在内的代谢性疾病。此新型口服小分子选择性胰淀素受体激动剂进一步扩充了歌礼现有的胰淀素多肽管线，该管线包括ASC36。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1512105.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBJ","BK1515","PSYK","BK1191","BK1574","BK4588","LABU","IBBQ","BK1161","01477","BMED","MDTX","BK4585","01672"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascletis.com","stockEarnings":[{"period":"1week","weight":-0.0614},{"period":"1month","weight":-0.463},{"period":"3month","weight":-0.5614},{"period":"6month","weight":-0.711},{"period":"1year","weight":-0.4697},{"period":"ytd","weight":-0.5702}],"compareEarnings":[{"period":"1week","weight":0.0801},{"period":"1month","weight":0.0213},{"period":"3month","weight":-0.0339},{"period":"6month","weight":-0.0605},{"period":"1year","weight":-0.0439},{"period":"ytd","weight":-0.0325}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"歌礼制药有限公司是一家主要从事医药产品研发、生产和销售的投资控股公司。该公司专注于病毒性疾病、非酒精性脂肪性肝炎（NASH）或原发性胆汁性胆管炎（PBC）及肿瘤领域。该公司的产品管线包括用于慢性乙肝功能性治愈的ASC22、用于呼吸道合胞病毒（RSV）的ASC10、用于人类免疫缺陷病毒（HIV）功能性治愈的ASC22、用於新冠肺炎的ASC10及ASC11、用於NASH的ASC41、用於PBC的ASC42、用于实体瘤的ASC61、用于中、重度痤疮的ASC40等。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.146882},{"month":2,"riseRate":0.75,"avgChangeRate":0.100059},{"month":3,"riseRate":0.375,"avgChangeRate":-0.044472},{"month":4,"riseRate":0.375,"avgChangeRate":-0.053142},{"month":5,"riseRate":0.375,"avgChangeRate":-0.01034},{"month":6,"riseRate":0.375,"avgChangeRate":-0.053675},{"month":7,"riseRate":0.5,"avgChangeRate":0.001982},{"month":8,"riseRate":0.375,"avgChangeRate":-0.008209},{"month":9,"riseRate":0.111111,"avgChangeRate":-0.083211},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.066621},{"month":11,"riseRate":0.777778,"avgChangeRate":0.164706},{"month":12,"riseRate":0.5,"avgChangeRate":0.087327}],"exchange":"SEHK","name":"歌礼制药-B","nameEN":"ASCLETIS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供歌礼制药-B(01672)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"歌礼制药-B,01672,歌礼制药-B股票,歌礼制药-B股票老虎,歌礼制药-B股票老虎国际,歌礼制药-B行情,歌礼制药-B股票行情,歌礼制药-B股价,歌礼制药-B股市,歌礼制药-B股票价格,歌礼制药-B股票交易,歌礼制药-B股票购买,歌礼制药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供歌礼制药-B(01672)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}